Stocks
Passage Bio, Inc.PASG
NASDAQHealthcareBiotechnology$3.51
Price as of · delayed, not real-time
A clinical-stage gene therapy developer focused on treatments for rare monogenic central nervous system disorders. Its lead candidate, PBML01, targets frontotemporal dementia, with additional programs in GM1 gangliosidosis and Krabbe disease. Investors track the company for its progress in CNS gene therapy delivery and its partnerships with academic institutions.
52W Range: $3.29-$20.00
Congressional Interest in Passage Bio, Inc. (PASG)
No congressional trades have been disclosed for Passage Bio, Inc. (PASG) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading PASG?
No congressional trades found for this stock.